39
Participants
Start Date
March 15, 2022
Primary Completion Date
July 17, 2023
Study Completion Date
July 17, 2023
spesolimab
spesolimab
Tianjin Medical University General Hospital, Tianjin
Beijing Friendship Hospital, Beijing
The First Hospital of China Medical University, Shenyang
Shanghai Skin Disease Hospital, Shanghai
Dermatology Hospital, Chinese Academy of Medical Sciences, Nanjing
Shandong Provincial Hospital of Dermatology, Jinan
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
Hangzhou Third People's Hospital, Hangzhou
Wuhan Union Hospital, Wuhan
Southern Medical University Dermatology Hospital, Guangzhou
The University of Hong Kong-Shenzhen Hospital, Shenzhen
West China Hospital, Chengdu
Lead Sponsor
Boehringer Ingelheim
INDUSTRY